Vir Biotechnology, Inc.

IAVI’s rVSVdeltaG-LASV-GPC, which is the first Lassa fever vaccine candidate to be evaluated in a Phase II trial, is among the first two products in 2025 to secure a place on PRIME, the European Medic

Vir Biotechnology’s move from focusing solely on antiviral drugs to incorporating oncology into its pipeline has shown early signs of potentially paying off as the company announced safety and efficac

Hepatitis D has so far largely resisted pharmaceutical intervention, with only one specifically approved product and several high-profile failures underlining the disease’s intractability. However, mi

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Crown Will Offer $924m To Merge With Re